CAMP4 Therapeutics
CAMP
46 hedge funds and large institutions have $176M invested in CAMP4 Therapeutics in 2026 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
15% more funds holding
Funds holding: 40 → 46 (+6)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4.96% less ownership
Funds ownership: 81.58% → 76.62% (-5%)
25% less capital invested
Capital invested by funds: $235M → $176M (-$59.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$5.51M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.1M |
| 3 |
SC
SummitTX Capital
Fort Worth,
Texas
|
+$1.61M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$928K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ES
Enavate Sciences
Menlo Park,
California
|
-$4.01M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.99M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.23M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.05M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$213K |
CAMP Hedge Fund Activity: Q1 2026 in Review
46 of the 8,132 institutional investors tracked by Wall St. Rank reported a position in CAMP4 Therapeutics (CAMP) for Q1 2026, worth a combined $176M — down 25% from $235M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CAMP positions and 7 closed out — a net gain of 7 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $5.51M. The largest seller was Enavate Sciences, cutting an estimated $4.01M.
- 46 institutional investors held CAMP4 Therapeutics (CAMP) as of Q1 2026, up from 40 in Q4 2025.
- Funds reported $176M of CAMP4 Therapeutics stock for Q1 2026, down 25% quarter-over-quarter.
- 14 funds opened new CAMP4 Therapeutics positions in Q1 2026 and 7 closed out, a net change of +7 holders.
- The largest CAMP4 Therapeutics buyer in Q1 2026 was Stonepine Capital Management, an estimated $5.51M added.
- The largest CAMP4 Therapeutics seller in Q1 2026 was Enavate Sciences, an estimated $4.01M sold.
Based on aggregated 13F filings for Q1 2026.